Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96NR8
UPID:
RDH12_HUMAN
Alternative names:
All-trans and 9-cis retinol dehydrogenase; Short chain dehydrogenase/reductase family 7C member 2
Alternative UPACC:
Q96NR8; B2RDA2; Q8TAW6
Background:
Retinol dehydrogenase 12 (RDH12) functions as a retinoids dehydrogenase/reductase, primarily converting various forms of retinal, including 9-cis, 11-cis, and all-trans-retinal, with a preference for NADP. It exhibits activity towards lipid peroxidation products, playing a crucial role in detoxifying toxic aldehyde products in photoreceptor cells. Despite its weak activity towards 13-cis-retinol, RDH12's involvement in visual processes and cellular detoxification underscores its biological significance.
Therapeutic significance:
RDH12 is implicated in severe retinal dystrophies, such as Leber congenital amaurosis 13 and Retinitis pigmentosa 53, diseases characterized by early-onset vision loss and progressive retinal degeneration. Understanding the role of RDH12 could open doors to potential therapeutic strategies, offering hope for interventions that could mitigate or reverse the progression of these debilitating visual impairments.